The current results are published in the November 25 issue of Neurology. The researchers were led by Eric J. Sorenson, MD, from the Mayo Clinic in Rochester, Minnesota ""While this is very disappointing, at least it was definitive and gives, I think, a pretty definitive answer, at least for this strategy for this drug,"" Dr. Sorenson said. However, he added, ""there is still a great deal of evidence that the IGF-1 pathway can be beneficial to people who have ALS, but just not the way we administered it.""